Saturday, 31 October 2026European Markets

CLARANOVA Stock Bullish By 28% In The Last 10 Sessions

Loading stream...

claranova, a multinational technology company, saw a significant increase in its share value recently. over a period of just 10 trading sessions, the value of the company's shares surged by 28.57%, moving from eur1.4 to eur1.80 by wednesday afternoon. interestingly, this substantial increase took place even though claranova's share value ended notably lower than its 52-week peak of eur3.93.

claranova's operations and financial health

claranova operates in various global markets including the u.s., u.k., germany, france and other european regions. the company's main business segments include personalized e-commerce, software publishing and the burgeoning sector of internet of things. however, claranova's recent financial performance has been characterized by a negative eps of eur-0.4 and an roe of a deeply negative 143.31%. both these measures point towards a declining profitability in recent times.

stock performance and volatility

despite experiencing considerable fluctuations in intraday trading volatility over the preceding quarter, claranova's stock managed to exceed its 50-day moving average of eur1.73. nevertheless, it still stood considerably lower than its 200-day moving average of eur2.18.

revenue growth and net revenue

certain recent changes in claranova's stock price could potentially be attributed to its excellent quarterly revenue growth of 12.5% year-on-year, and the fact that its annual net revenue topped 508.5m over 12 months.

investor considerations

claranova's recent encouraging stock performance could potentially signal the onset of a recovery. however, it is crucial that prospective and current investors study its vital financial health indicators and balance this information with an analysis of the overall cac 40 index performance and sector-specific considerations prior to making any investment decisions.

more news about claranova (cla.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com